Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

FDA announces new insulin recall due to potential labeling issue

The recall is focused on a single batch distributed from December 2021 to March 2022.

Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Renal denervation linked to significant blood pressure reductions after 3 years

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet

AI model able to ID early signs of type 2 diabetes on imaging results

The authors hope their findings could lead to earlier diagnoses and improvements in patient care. 

Steven E. Nissen, MD, discusses his late-breaking clinical trial with panelist Vera Bittner, MD.

Cholesterol medications, flu shots and heart failure: Day 2 at ACC.22

Day 2 of ACC.22 was jam-packed with late-breaking clinical trials. Read our quick rundown of what researchers shared with the public for the very first time. 

ACC.22 kicked off on Saturday, April 2, in Washington, D.C.

Salt restrictions, PCI breakthroughs and a social media primer for cardiologists: Day 1 at ACC.22

Explore our on-the-ground coverage of the first day of ACC.22.

Cardiology groups debut new heart failure guidelines ahead of ACC.22

The new recommendations went live just ahead of ACC.22. They can be read in full in the Journal of the American College of Cardiology, Circulation or Journal of Cardiac Failure.

Regularly eating avocados is associated with a reduced risk of cardiovascular disease, according to a new study.

Eating avocados lowers CVD risk

The new analysis, published in the Journal of the American Heart Association, included patient data from the last three decades.